Trial Profile
Magnetoencephalography / Magnetic Resonance Spectroscopy Dose Response Study of Arbaclofen in Autism Spectrum Disorder
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Arbaclofen (Primary)
- Indications Autistic disorder; Pervasive child development disorders
- Focus Therapeutic Use
- 27 Sep 2019 Status changed from active, no longer recruiting to completed.
- 14 Mar 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jul 2019.
- 19 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Jan 2019.